DNMT3A and acute myeloid leukemia: Our results identified that AML cells with a DNMT3A R882H mutation were not as sensitive to DNR as that of DNMT3A WT cells, which was in line with previous studies that confirmed that a high-dose daunorubicin improves the outcome of AML with a DNMT3A mutation [12, 13, 59].Then exploring how DNMT3A R882H mutation influence AML cells’ sensitivity to DNR is of great importance to improve the prognosis of AML patients after DNR treatment.